SEC Tracker
Get the app

Yubo International Biotech YBGJ

Yubo International Biotech reports $0 revenue and $188,376 net loss

Yubo International Biotech (YBGJ) filed a 10-Q with the SEC on Nov 10, 2026, 5:30 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $0 for the three months ended Sep 30, 2026
  2. Net loss: $188,376 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $9,465 at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Going-concern warning repeated

“These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time.”
In the notes to the financial statements. Read it in the filing 10-Q on EDGAR

Also in the prior 10-Q (filed Aug 14, 2026). Prior report Prior on EDGAR

Quoted from the filing.

Get an email when Yubo International Biotech files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$0$0—
Operating income and margin−$203K−$239K+15%
Net income−$188K−$248K+24%
Operating cash flow−$157−$84K+100%
Cash$9K$12K−21%

Data on this page was fetched . The filing on SEC.gov is the record.